lisocabtagene maraleucel,ibrutinib,venetoclax
BMS,Roche,Abbvie
['bms', 'bmsnews']
icymi: reported that results seen in the trial s broader population were consistent with results from the peas group. #asco23 read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.